01—Abstract
Summary
Summary of the 8-K filed July 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported second-quarter 2025 results for the period ended June 30, 2025, with total net product sales of $682 milliona, which the company describes as 17% year-over-year growth.
INGREZZA net product sales were $624 millionb, up 15% sequentially from the first quarter and 8% year-over-year, and the company said the return to volume growth was driven by strong patient demand and a quarterly record in new prescriptions. CRENESSITY, the company's newer product, generated $53 million in net product sales, with 664 new patient enrollment start forms in the quarter and 76% reimbursement coverage for dispensed scripts. Total revenues were $687.5 million.
GAAP net income was $107.5 millionc, or $1.06 per diluted share, versus $65.0 million, or $0.63 per diluted share, a year earlier. Non-GAAP net income was $166.2 million, or $1.65 per diluted share, compared with $168.9 million, or $1.63, in the prior-year quarter. The company narrowed its 2025 INGREZZA net product sales guidance to $2.5 billion to $2.55 billion, down from $2.5 billion to $2.6 billion, citing double-digit volume growth partially offset by lower net price from expanded access.
It also updated full-year GAAP R&D expense guidance to $960 million to $1.01 billiond and GAAP SG&A expense guidance to $1.135 billion to $1.155 billion. R&D guidance includes $60 million of development milestone expense tied to collaborations with Takeda and Nxera. Pipeline news was mixed.
A Phase 3 study of adjunctive valbenazine in schizophrenia did not meet its primary endpoint, although the company cited consistent trends and a statistically significant effect in the PANSS positive symptom domain. The company initiated a Phase 3 registrational program for NBI-'568, an oral M4 selective muscarinic agonist, in schizophrenia, and began a Phase 1 study of NBIP-1435 for congenital adrenal hyperplasia. Cash, cash equivalents, and marketable securities totaled $1.85 billion at June 30, 2025, and $332 million remained under a $500 million share repurchase program.
02—Key points
Key Highlights
- Total net product sales of $682 million in Q2 2025, which the company describes as 17% year-over-year growth.
- INGREZZA net product sales of $624 million, up 15% sequentially and 8% year-over-year, with a return to volume growth and a quarterly record in new prescriptions.
- CRENESSITY net product sales of $53 million, with 664 new patient enrollment start forms and 76% reimbursement coverage for dispensed scripts.
- GAAP diluted EPS of $1.06 versus $0.63 a year earlier; non-GAAP diluted EPS of $1.65 versus $1.63.
- 2025 INGREZZA net product sales guidance narrowed to $2.5 billion to $2.55 billion from $2.5 billion to $2.6 billion; GAAP R&D and SG&A expense guidance updated.
- Phase 3 study of adjunctive valbenazine in schizophrenia missed its primary endpoint; the company initiated a Phase 3 program for NBI-'568 in schizophrenia.
- Cash, cash equivalents, and marketable securities of about $1.8 billion at June 30, 2025, with $332 million remaining under the $500 million share repurchase program.
03—Questions
Frequently Asked Questions
How did INGREZZA perform in the second quarter of 2025?
INGREZZA net product sales were $624 million, up 15% sequentially from the first quarter of 2025 and 8% year-over-year. The company attributed the return to volume growth to strong patient demand and a new quarterly record in new prescriptions, while noting that expanded formulary access is expected to lower net price.
What is the status of CRENESSITY's launch?
CRENESSITY generated $53 million in second-quarter 2025 net product sales. The company reported 664 total new patient enrollment start forms in the quarter, 1,077 for the first half of 2025, and 76% reimbursement coverage for dispensed scripts. The CEO described demand as robust while noting the launch is still early.
What changed in the company's 2025 financial guidance?
The company narrowed its 2025 INGREZZA net product sales guidance to $2.5 billion to $2.55 billion from $2.5 billion to $2.6 billion. It also set GAAP R&D expense guidance of $960 million to $1.01 billion and GAAP SG&A expense guidance of $1.135 billion to $1.155 billion. R&D guidance includes $60 million of development milestone expense.
What were the setbacks in the pipeline this quarter?
A Phase 3 study of adjunctive valbenazine for schizophrenia did not meet its primary endpoint, though the company cited consistent favorable trends and a statistically significant effect in the PANSS positive symptom domain. The company said the insights will inform development of its next-generation VMAT2 inhibitors, and full results will be published at a later date.
How much cash does the company have, and what is its capital return activity?
Cash, cash equivalents, and marketable securities totaled $1,849.4 million at June 30, 2025, compared with $1,815.6 million at December 31, 2024. Under a share repurchase program authorized February 21, 2025 for up to $500 million, the company had repurchased $168 million of stock as of June 30, 2025, including $18 million in the second quarter, leaving $332 million available.
04—Continue